← Leaderboards
Stephen Y Chan
Brigham And Women'S Hospital
$16,563,292
Attributed
$20,231,325
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,231,325 · 9
By mechanism
R01$17,625,220 · 5
P50$1,149,521 · 1
K08$687,225 · 1
UH2$614,554 · 1
UH3$154,805 · 1
Top collaborators
- Panagiotis V Benos5 shared
- Alison Morris5 shared
- Karen A Norris4 shared
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungMolecularLinkBlood VesselsCellsMetabolismIn VivoEndotheliumNew Therapeutic TargetRodentPathway InteractionsPulmonary HypertensionVascular DiseasesBaseEndothelial CellsProteinsRegulationSignal TransductionGeneticMicrornasMetabolicPathogenicityPhenotypeHypoxia
Grant awards (44)
An endothelial-fibroblast axis connecting senescence to amino acid metabolism for control of vascular stiffness in PAH$760,713
R01 · FY2025 · HL · contact PI
Genetic and hypoxic control of a lncRNA axis orchestrates endothelial reprogramming in pulmonary hypertension$687,185
R01 · FY2025 · HL · contact PI
A platelet-fibroblast axis connecting bioenergetics and metabolism in SSc-pulmonary arterial hypertension$234,488
P50 · FY2025 · AR · contact PI
An endothelial-fibroblast axis connecting senescence to amino acid metabolism for control of vascular stiffness in PAH$745,499
R01 · FY2024 · HL · contact PI
Genetic and hypoxic control of a lncRNA axis orchestrates endothelial reprogramming in pulmonary hypertension$686,433
R01 · FY2024 · HL · contact PI
Frataxin deficiency as a cause of endothelial senescence in multiple subtypes of pulmonary hypertension$604,344
R01 · FY2024 · HL · contact PI
A platelet-fibroblast axis connecting bioenergetics and metabolism in SSc-pulmonary arterial hypertension$303,064
P50 · FY2024 · AR · contact PI
An endothelial-fibroblast axis connecting senescence to amino acid metabolism for control of vascular stiffness in PAH$789,261
R01 · FY2023 · HL · contact PI
Genetic and hypoxic control of a lncRNA axis orchestrates endothelial reprogramming in pulmonary hypertension$737,433
R01 · FY2023 · HL · contact PI
Frataxin deficiency as a cause of endothelial senescence in multiple subtypes of pulmonary hypertension$616,679
R01 · FY2023 · HL · contact PI
A platelet-fibroblast axis connecting bioenergetics and metabolism in SSc-pulmonary arterial hypertension$305,614
P50 · FY2023 · AR · contact PI
An endothelial-fibroblast axis connecting senescence to amino acid metabolism for control of vascular stiffness in PAH$789,976
R01 · FY2022 · HL · contact PI
Frataxin deficiency as a cause of endothelial senescence in multiple subtypes of pulmonary hypertension$619,875
R01 · FY2022 · HL · contact PI
A platelet-fibroblast axis connecting bioenergetics and metabolism in SSc-pulmonary arterial hypertension$306,355
P50 · FY2022 · AR · contact PI
Systems Biology of Diffusion Impairment in HIV$773,874
R01 · FY2021 · HL
Frataxin deficiency as a cause of endothelial senescence in multiple subtypes of pulmonary hypertension$617,569
R01 · FY2021 · HL · contact PI
Systems Biology of Diffusion Impairment in HIV$774,369
R01 · FY2020 · HL
Systems Biology in Vaping Product Exposure$572,242
R01 · FY2020 · HL
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$412,816
R01 · FY2020 · HL · contact PI
Systems Biology of Diffusion Impairment in HIV$774,849
R01 · FY2019 · HL
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$499,098
R01 · FY2019 · HL · contact PI
Iron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary Hypertension$391,250
R01 · FY2019 · HL · contact PI
Computational repurposing of chemotherapies for pulmonary hypertension$154,805
UH3 · FY2019 · TR · contact PI
Systems Biology of Diffusion Impairment in HIV$775,316
R01 · FY2018 · HL
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$756,459
R01 · FY2018 · HL · contact PI
Iron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary Hypertension$390,626
R01 · FY2018 · HL · contact PI
Defining the Complex Biology of the miR-130/301 Family in Pulmonary Hypertension$357,307
R01 · FY2018 · HL · contact PI
Computational repurposing of chemotherapies for pulmonary hypertension$306,896
UH2 · FY2018 · TR · contact PI
Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension$773,494
R01 · FY2017 · HL · contact PI
Iron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary Hypertension$387,419
R01 · FY2017 · HL · contact PI
Defining the Complex Biology of the miR-130/301 Family in Pulmonary Hypertension$355,363
R01 · FY2017 · HL · contact PI
Computational repurposing of chemotherapies for pulmonary hypertension$307,658
UH2 · FY2017 · TR · contact PI
Iron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary Hypertension$402,875
R01 · FY2016 · HL · contact PI
Defining the Complex Biology of the miR-130/301 Family in Pulmonary Hypertension$336,558
R01 · FY2016 · HL · contact PI
Defining the Complex Biology of the miR-130/301 Family in Pulmonary Hypertension$322,934
R01 · FY2015 · HL · contact PI
Iron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary Hypertension$239,747
R01 · FY2015 · HL · contact PI
Iron-Sulfur Deficiency as a Critical Pathogenic Cause of Pulmonary Hypertension$181,848
R01 · FY2015 · HL · contact PI
Defining the complex biology of the miR-130/301 family in pulmonary hypertension$72,221
R01 · FY2015 · HL · contact PI
Defining the complex biology of the miR-130/301 family in pulmonary hypertension$419,588
R01 · FY2014 · HL · contact PI
Functions of the Hypoxia-Induced MicroRNA-210 in Pulmonary Vascular Endothelium$137,445
K08 · FY2014 · HL · contact PI
Functions of the Hypoxia-Induced MicroRNA-210 in Pulmonary Vascular Endothelium$137,445
K08 · FY2013 · HL · contact PI
Functions of the Hypoxia-Induced MicroRNA-210 in Pulmonary Vascular Endothelium$137,445
K08 · FY2012 · HL · contact PI
Functions of the Hypoxia-Induced MicroRNA-210 in Pulmonary Vascular Endothelium$137,445
K08 · FY2011 · HL · contact PI
Functions of the Hypoxia-Induced MicroRNA-210 in Pulmonary Vascular Endothelium$137,445
K08 · FY2010 · HL · contact PI